A landmark clinical trial has demonstrated that CRISPR-Cas9 gene editing can cure sickle cell disease, one of the most common and debilitating genetic disorders affecting millions of people worldwide. The trial, conducted across 15 medical centers in the United States, Europe, and India, enrolled 42 patients with severe sickle cell disease and treated them with a single infusion of gene-edited cells. After two years of follow-up, all 42 patients remain free of the severe pain crises that characterize the disease, and 38 of the 42 show no detectable sickle cells in their blood.
How CRISPR Cures Sickle Cell Disease
Sickle cell disease is caused by a mutation in the gene that encodes hemoglobin, the protein in red blood cells that carries oxygen. The mutation causes hemoglobin to form rigid, sickle-shaped structures that block blood vessels, causing severe pain, organ damage, and shortened life expectancy. The CRISPR treatment works by editing patients own stem cells to reactivate fetal hemoglobin — a form of hemoglobin that is naturally produced before birth and is not affected by the sickle cell mutation.
The treatment process involves collecting stem cells from the patient bone marrow, using CRISPR to edit a gene called BCL11A that normally suppresses fetal hemoglobin production, and infusing the edited cells back into the patient after chemotherapy to clear the existing bone marrow. The edited cells repopulate the bone marrow and produce red blood cells containing fetal hemoglobin, which functions normally and does not sickle.
Impact on Patients
The impact on patients quality of life has been transformative. Before treatment, participants averaged 4-7 severe pain crises per year, each requiring hospitalization. After treatment, the average number of pain crises dropped to zero. Patients who had been unable to work or attend school due to the unpredictability of their disease have returned to normal activities. Several participants have described the treatment as giving them their lives back.
Regulatory Approval and Access
The FDA approved the first CRISPR-based treatment for sickle cell disease in December 2023, and the European Medicines Agency followed with approval in early 2024. The treatment, marketed as Casgevy by Vertex Pharmaceuticals and CRISPR Therapeutics, is priced at 2.2 million dollars per patient — making it one of the most expensive medical treatments ever approved. Access for patients in developing countries, where sickle cell disease is most prevalent, remains a major challenge that researchers and policymakers are working to address.
